Literature DB >> 25753457

Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.

Gabriella Santangelo1, Carmine Vitale2, Marina Picillo3, Sofia Cuoco4, Marcello Moccia5, Domenica Pezzella4, Roberto Erro6, Katia Longo7, Caterina Vicidomini8, Maria Teresa Pellecchia3, Marianna Amboni7, Arturo Brunetti9, Marco Salvatore9, Paolo Barone10, Sabina Pappatà11.   

Abstract

INTRODUCTION: Apathy is a neuropsychiatric symptom in Parkinson's Disease (PD) which has a negative impact on quality of life and might be related in part to damage of presynaptic dopaminergic system. Little is known about relationship between striatal dopamine levels and apathy in PD patients without dementia and/or depression. The aim of the present study was to investigate the relationship between "pure apathy" and striatal dopamine uptake in untreated, drug-naïve PD patients without clinically significant dementia and/or depression.
METHODS: Fourteen PD patients with pure apathy and 14 PD patients without apathy, matched for age, side of motor symptoms at onset, motor disability and disease duration, underwent both neuropsychological and behavioral examination including self-rated version of the Apathy Evaluation Scale (AES-S). All patients underwent 123 I-FP-CIT (DaT-SCAN) SPECT to assess dopamine transporter (DAT) striatal uptake.
RESULTS: PD patients with apathy showed lower DAT levels in the striatum than non-apathetic patients. After Bonferroni correction the difference between groups was significant in the right caudate.
CONCLUSIONS: Apathy is associated with reduced striatal dopamine transporter levels, independent of motor disability and depression in non-demented PD patients. These findings suggest that dysfunction of dopaminergic innervation in the striatum and particularly in the right caudate may contribute to development of apathy in early PD.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apathy; Behavioral disorders; Dopamine; Non-motor symptoms; Parkinson's disease; [123] FP-CIT SPECT

Mesh:

Substances:

Year:  2015        PMID: 25753457     DOI: 10.1016/j.parkreldis.2015.02.015

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  32 in total

Review 1.  Inhibitory dysfunction contributes to some of the motor and non-motor symptoms of movement disorders and psychiatric disorders.

Authors:  Marjan Jahanshahi; John C Rothwell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-04-19       Impact factor: 6.237

Review 2.  Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.

Authors:  Stephane Thobois; Stephane Prange; Véronique Sgambato-Faure; Léon Tremblay; Emmanuel Broussolle
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-18       Impact factor: 5.081

Review 3.  Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson's Disease: What Do Clinical and Neuroimaging Studies Tell Us?

Authors:  Alexandru Hanganu; Oury Monchi
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-15       Impact factor: 5.081

4.  Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Authors:  Gabriella Santangelo; Sofia Cuoco; Maria Teresa Pellecchia; Roberto Erro; Paolo Barone; Marina Picillo
Journal:  J Neurol       Date:  2018-09-03       Impact factor: 4.849

5.  Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson's disease patients with impulse control disorders.

Authors:  I Navalpotro-Gomez; R Dacosta-Aguayo; F Molinet-Dronda; A Martin-Bastida; A Botas-Peñin; H Jimenez-Urbieta; M Delgado-Alvarado; B Gago; A Quiroga-Varela; Maria C Rodriguez-Oroz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-04       Impact factor: 9.236

Review 6.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

7.  Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson's disease without dementia.

Authors:  Yoon-Sang Oh; Jean Hee Kim; Sang-Won Yoo; Eo-Jin Hwang; Chul Hyoung Lyoo; Kwang-Soo Lee; Joong-Seok Kim
Journal:  Neurol Sci       Date:  2020-10-31       Impact factor: 3.307

8.  Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease.

Authors:  Marina Picillo; Gabriella Santangelo; Marcello Moccia; Roberto Erro; Marianna Amboni; Elio Prestipino; Katia Longo; Carmine Vitale; Emanuele Spina; Giuseppe Orefice; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neural Transm (Vienna)       Date:  2016-01-06       Impact factor: 3.575

9.  Evolution of Apathy in Early Parkinson's Disease: A 4-Years Prospective Cohort Study.

Authors:  Ruwei Ou; Junyu Lin; Kuncheng Liu; Zheng Jiang; Qianqian Wei; Yanbing Hou; Lingyu Zhang; Bei Cao; Bi Zhao; Wei Song; Huifang Shang
Journal:  Front Aging Neurosci       Date:  2021-01-28       Impact factor: 5.750

10.  Bidirectional Correlations Between Dopaminergic Function and Motivation in Parkinson's Disease.

Authors:  Jared T Hinkle; Kelly A Mills; Kate Perepezko; Gregory M Pontone
Journal:  J Geriatr Psychiatry Neurol       Date:  2021-02-24       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.